BE890369A - Nouveaux medicaments a base d'inhibiteurs de la secretion de la prolactine pour le traitement de l'arteriosclerose - Google Patents
Nouveaux medicaments a base d'inhibiteurs de la secretion de la prolactine pour le traitement de l'arteriosclerose Download PDFInfo
- Publication number
- BE890369A BE890369A BE1/10317A BE1010317A BE890369A BE 890369 A BE890369 A BE 890369A BE 1/10317 A BE1/10317 A BE 1/10317A BE 1010317 A BE1010317 A BE 1010317A BE 890369 A BE890369 A BE 890369A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- arteriosclerosis
- treatment
- prolactin
- secretion
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title claims description 7
- 230000028327 secretion Effects 0.000 title description 20
- 102000003946 Prolactin Human genes 0.000 title description 19
- 108010057464 Prolactin Proteins 0.000 title description 19
- 229940097325 prolactin Drugs 0.000 title description 19
- 238000011282 treatment Methods 0.000 title description 11
- 206010003210 Arteriosclerosis Diseases 0.000 title description 10
- 208000011775 arteriosclerosis disease Diseases 0.000 title description 10
- 239000003112 inhibitor Substances 0.000 title description 10
- 200000000007 Arterial disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 229950001817 alpha-ergocryptine Drugs 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 19
- 241000700159 Rattus Species 0.000 description 17
- 238000012360 testing method Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000003902 lesion Effects 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 7
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 229960002802 bromocriptine Drugs 0.000 description 5
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- TUMNHQRORINJKE-UHFFFAOYSA-N 1,1-diethylurea Chemical compound CCN(CC)C(N)=O TUMNHQRORINJKE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 231100001012 cardiac lesion Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- RHGUXDUPXYFCTE-ZWNOBZJWSA-N ergoline Chemical compound C1=CC([C@@H]2[C@H](NCCC2)C2)=C3C2=CNC3=C1 RHGUXDUPXYFCTE-ZWNOBZJWSA-N 0.000 description 1
- -1 flavorings Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8030228 | 1980-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE890369A true BE890369A (fr) | 1982-03-16 |
Family
ID=10516153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE1/10317A BE890369A (fr) | 1980-09-18 | 1981-09-16 | Nouveaux medicaments a base d'inhibiteurs de la secretion de la prolactine pour le traitement de l'arteriosclerose |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5782317A (it) |
| AU (1) | AU7544281A (it) |
| BE (1) | BE890369A (it) |
| IT (1) | IT1210577B (it) |
| PH (1) | PH20494A (it) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2571962A1 (fr) * | 1984-10-24 | 1986-04-25 | Sandoz Sa | Nouvelles formulations galeniques a base de bromocriptine. |
| US5006526A (en) * | 1988-10-17 | 1991-04-09 | Louisiana State University | Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis |
| US5344832A (en) * | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| US5468755A (en) * | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
| US5679685A (en) * | 1993-12-22 | 1997-10-21 | Ergo Science, Incorporated | Accelerated release composition containing bromocriptine |
| US5700800A (en) * | 1988-05-10 | 1997-12-23 | Ergo Science Incorporated | Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound |
| US5700795A (en) * | 1988-05-10 | 1997-12-23 | The General Hospital Corporation | Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of type II diabetes |
| US5866584A (en) * | 1988-05-10 | 1999-02-02 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of type II diabetes |
| US5902811A (en) * | 1995-05-31 | 1999-05-11 | Ergo Research Corporation | Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions |
| US6004972A (en) * | 1988-05-10 | 1999-12-21 | The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of type II diabetes |
| US6855707B2 (en) | 1996-05-07 | 2005-02-15 | Pliva D.D. | Method for the treatment of lipid and glucose metabolism disorders |
-
1981
- 1981-09-16 BE BE1/10317A patent/BE890369A/fr not_active IP Right Cessation
- 1981-09-17 AU AU75442/81A patent/AU7544281A/en not_active Abandoned
- 1981-09-17 JP JP56147731A patent/JPS5782317A/ja active Pending
- 1981-09-18 IT IT8149328A patent/IT1210577B/it active
- 1981-12-07 PH PH26589A patent/PH20494A/en unknown
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2571962A1 (fr) * | 1984-10-24 | 1986-04-25 | Sandoz Sa | Nouvelles formulations galeniques a base de bromocriptine. |
| US5712265A (en) * | 1988-05-10 | 1998-01-27 | The General Hospital Corporation | Administration of pirenzepine, methyl scopolamine and other muscarinin receptor antagonists for treatment of glucose metabolism disorders |
| US5854255A (en) * | 1988-05-10 | 1998-12-29 | Ergo Research Corporation | Therapeutic package for the long term reduction of body fat stores insulin resistance hyperinsulinemia and hyperglycemia in vertebrates |
| US5468755A (en) * | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
| US5554623A (en) * | 1988-05-10 | 1996-09-10 | Ergo Science Incorporated | Method for the long term reduction of body fat stores, insulin resistance, hypersinsulinemia and hyperglycemia in vertebrates |
| US5635512A (en) * | 1988-05-10 | 1997-06-03 | Ergo Science Incorporated | Method for modifying or resetting the prolactin rhythm of an insulin insensitive or diabetic animal or human |
| US5654313A (en) * | 1988-05-10 | 1997-08-05 | Ergo Science Incorporated | Method for modifying or regulating the glucose metabolism of an animal or human subject |
| US6004972A (en) * | 1988-05-10 | 1999-12-21 | The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of type II diabetes |
| US5700800A (en) * | 1988-05-10 | 1997-12-23 | Ergo Science Incorporated | Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound |
| US5700795A (en) * | 1988-05-10 | 1997-12-23 | The General Hospital Corporation | Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of type II diabetes |
| US5866584A (en) * | 1988-05-10 | 1999-02-02 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of type II diabetes |
| US5719160A (en) * | 1988-05-10 | 1998-02-17 | The Board Of Supervisors Of Louisiana State And Agricultural And Mechanical College | Method for modifying and regulating lipid metabolism |
| US5716962A (en) * | 1988-05-10 | 1998-02-10 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Process for therapeutically modifying and resetting prolactin rhythm with a dopamine agonist |
| US5716957A (en) * | 1988-05-10 | 1998-02-10 | The Board Of Supervisors Of Louisiana State And Agricultural And Mechanical College | Method for modifying and resetting the bloodstream prolactin levels of a human subject |
| US5731312A (en) * | 1988-05-10 | 1998-03-24 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| US5750519A (en) * | 1988-05-10 | 1998-05-12 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| US5756513A (en) * | 1988-05-10 | 1998-05-26 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of type II diabetes |
| US5006526A (en) * | 1988-10-17 | 1991-04-09 | Louisiana State University | Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis |
| US5344832A (en) * | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| US5679685A (en) * | 1993-12-22 | 1997-10-21 | Ergo Science, Incorporated | Accelerated release composition containing bromocriptine |
| US5902811A (en) * | 1995-05-31 | 1999-05-11 | Ergo Research Corporation | Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions |
| US6855707B2 (en) | 1996-05-07 | 2005-02-15 | Pliva D.D. | Method for the treatment of lipid and glucose metabolism disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| PH20494A (en) | 1987-01-21 |
| AU7544281A (en) | 1982-03-25 |
| IT8149328A0 (it) | 1981-09-18 |
| IT1210577B (it) | 1989-09-14 |
| JPS5782317A (en) | 1982-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1601349B1 (fr) | Utilisation de l'énantiomère (1S, 2R) du milnacipran pour la préparation d'un médicament | |
| FR2629716A1 (fr) | Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique | |
| BE890369A (fr) | Nouveaux medicaments a base d'inhibiteurs de la secretion de la prolactine pour le traitement de l'arteriosclerose | |
| EA014707B1 (ru) | Новая форма введения рацекадотрила | |
| FR2917975A1 (fr) | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains | |
| FR2484832A1 (fr) | Composition pharmaceutique utile pour le traitement de l'allergie | |
| CA2738875C (fr) | Composition veterinaire antiprolactinique destinee aux ruminants | |
| EP2305225A1 (fr) | Utilisation de l'enantiomere (1s, 2r) du milnacipran pour la preparation d'un medicament | |
| FR2530468A1 (fr) | Composition analgesique et anti-inflammatoire contenant de l'ibuprofen | |
| FR2505184A1 (fr) | Procede de prevention de la paralysie vitulaire chez la vache laitiere | |
| EP1572692A1 (fr) | Enantiomere (-) du tenatoprazole et son application en therapeutique | |
| WO2017085407A1 (fr) | Mirabégron pour le traitement de maladies rétiniennes | |
| JP6971997B2 (ja) | 個体における尿中シュウ酸塩濃度を低下させるための、スチリペントール及びその誘導体の使用 | |
| EP3648768B1 (fr) | Iméglimine pour la prévention et/ou le traitement du carcinome hépatocellulaire | |
| BE896621A (fr) | Nouvelle utilisation therapeutique d'analogues de prostaglandines | |
| CH665637A5 (fr) | 5-(3-n-butyloxalylaminophenyl)tetrazole comme agent antiasthmatique, composition le contenant et procede de preparation de la composition. | |
| WO2015140747A1 (fr) | Utilisation d'une composition vétérinaire à base de torasémide pour une administration à faible dose | |
| FR2845916A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine | |
| BE890453A (fr) | Procede d'inhibition des metastases de cellules tumorales | |
| BE894696A (fr) | Nouveaux medicaments a base de 9,10-dihydro-ergonine pour le traitement de l'arteriosclerose | |
| EP1115399B1 (fr) | Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour la fabrication d'un medicament pour traiter les glomerulonephrites chroniques | |
| WO1996017616A1 (fr) | Trousse pour cycle de traitement de l'osteoporose | |
| FR2650502A1 (fr) | Nouvelle forme galenique orale ameliorant la biodisponibilite | |
| MC2019A1 (fr) | Composition pharmaceutique anti-hypertensive combinee | |
| FR2843303A1 (fr) | Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: SANDOZ S.A. Effective date: 19850930 |